SBIR-STTR Award

Enabling High Output Metabolism in Plant Cells
Award last edited on: 1/24/2006

Sponsored Program
SBIR
Awarding Agency
NSF
Total Award Amount
$574,937
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Michele M Champagne

Company Information

Kuehnle AgroSystems Corporation (AKA: Kuehnle AgroSystems Company LLC~Kuehnle AgroSystems Inc)

2800 Woodlawn Drive Suite 281
Honolulu, HI 96822
   (808) 721-3429
   heidi@kashawaii.com
   www.kuehnleagro.com
Location: Single
Congr. District: 01
County: Honolulu

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2004
Phase I Amount
$75,000
This Small Business Innovation Research (SBIR) Phase I project will demonstrate the technical feasibility of enhancing isoprenoid biosynthesis by mevalonate pathway addition to plastids of a eukaryotic model. Isoprenoids, as carotenoids, serve as natural colorants in plant products and also have a market as human dietary supplement. Increasing the output of carotenoids in cultivated plants and microalgae is of considerable interest as a way to provide these isoprenoids as natural products from renewable sources rather than from chemical synthesis. The commercial application of this project will be on the aquaculture and the ornamental horticulture industries

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
2005
Phase II Amount
$499,937
This Small Business Innovation Research (SBIR) Phase II project aims to develop and validate a novel chloroplast transformation vector for protein expression in chloroplasts. The research project will broaden scientific understanding of the parameters of chloroplast transformation by addressing stoichiometric expression of multiple transgenes for effective engineering of pathways such as carotenogenesis, feedback regulation and expression of multimeric proteins. The commercial impact of this technology will provide an enabling strategy for expression of genes of interest in chloroplasts to potentially increase the production of high value nutraceutical and pharmaceutical compounds. Application of this technology for stable, high output metabolism with regulatory compliance will reduce production cost and increase the reliability for downstream processing and eventual commercialization.